Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 10/20 | 0.35 |
| ▸ | PDE4A | P27815 | 7/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143842 | 0.94 | TNF (0.40) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4031151 | 0.91 | TNF (0.40) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4030294 | 0.87 | TNF (0.34) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2979242 | 0.85 | TNF (0.49) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3556544 | 0.85 | PDE4A (0.47) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4025658 | 0.83 | TNF (0.41) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2966972 | 0.80 | PDE4B (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3551861 | 0.77 | PDE4A (0.44) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3558073 | 0.77 | PDE4A (0.45) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3553803 | 0.75 | PDE4B (0.44) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | claimed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | claimed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | claimed |
| EP-1587474-A4 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1587474-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1587474-A3 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-09-15 | — | — | EP | claimed |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-10-14 | — | — | US | claimed |
| WO-2004060313-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1587474-B1 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090143382-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
| US-7504427-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | TRIMERIS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-7173058-B2 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1587474-A4 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1587474-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1587474-A3 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-09-15 | — | — | EP | disclosed |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-2004060313-A2 | FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143382-A1 | FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | PDE4A, PDE4B, PDE4D | TNF 4126/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20070072902-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | TNF 4126/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20040204448-A1 | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE4B, PDE4D | TNF 4126/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.